A detailed history of Macquarie Group LTD transactions in Fibrogen Inc stock. As of the latest transaction made, Macquarie Group LTD holds 4,647 shares of FGEN stock, worth $1,487. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,647
Holding current value
$1,487
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$0.89 - $2.36 $4,135 - $10,966
4,647 New
4,647 $4,000
Q3 2022

Nov 14, 2022

SELL
$11.4 - $14.6 $11,400 - $14,600
-1,000 Reduced 37.89%
1,639 $34,000
Q1 2021

May 14, 2021

BUY
$31.0 - $55.72 $10,447 - $18,777
337 Added 14.64%
2,639 $92,000
Q2 2020

Aug 11, 2020

BUY
$32.57 - $42.83 $12,278 - $16,146
377 Added 19.58%
2,302 $93,000
Q4 2019

Feb 14, 2020

SELL
$34.58 - $48.06 $57,921 - $80,500
-1,675 Reduced 46.53%
1,925 $83,000
Q3 2019

Nov 14, 2019

BUY
$36.98 - $48.45 $133,128 - $174,420
3,600 New
3,600 $133,000

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $30M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.